TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07441395: Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD

Sponsor: Corvus Pharmaceuticals, Inc. · Phase: PHASE2 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 200 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$8,256,000

Rescue Site Savings

+$5,443,800

Unlock Full NCT07441395 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07441395 Rescue Dossier →